Chris Lau
All posts from Chris Lau
Chris Lau in Value Stocks,

Does ARIAD Pharmaceuticals Has More Upside?

Do not look now, but ARIAD Pharmaceuticals (ARIA) is at yearly highs. After reporting a drop in costs, higher R&D spend, and higher revenue, the stock is holding steadily higher.

The company’s drug developments show promise. In the second quarter, the company started Phase 3 clinical trial of brigatinib in patients with ALK positive locally advanced or metastatic non- small cell lung cancer (source). The company reported Phase 2 PACE clinical trial of Iclusig results at the ASCO and EHA conferences.

AP32788 is showing promise for Ariad.

In the second quarter, ARIAD’s revenue grew 134% on Icusig sales. Though $25.5M is due to a one-time reimbursement, expect lower DSOs to translate to higher revenue growth.

Raising prices of Iclusig by $8 will also help gross profit margin.

ARIAD obviously has more upside, but value investors may want the stock pulling back before considering this stock.

Further reading: